Note 13 - Commitments and Contingencies (Details Textual) $ in Thousands		1 Months Ended		12 Months Ended
	Nov. 01, 2024 USD ($)	Jan. 31, 2023 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Nov. 07, 2022	Oct. 31, 2022 USD ($)	Jul. 18, 2014 USD ($)
Milestone Payments Maximum Amount				$ 287,300					$ 187,500
Potential Milestone Payments				102,500
Percentage of Unpaid Portion of Milestone Payments Interest Rate					6.25%
Milestone Payment			$ 1,800
Upfront License Fee				7,000
Acquired In-process Research and Development				0	$ 7,000	$ 0
Accrued Liabilities				52,842	60,425
Eshelman v. Puma Biotechnology, Inc. [Member]
Accrued Liabilities				7,700
Accrued Liabilities, Net Imputed Interest				8,000
Loss Contingency, Estimate of Possible Loss				$ 16,000
Legal Settlements Payments, Number of Installments				2			2
Payments for Legal Settlements		$ 8,000		$ 8,000	16,000
Eshelman v. Puma Biotechnology, Inc. [Member] | Forecast [Member]
Payments for Legal Settlements	$ 8,000
Clinical Trial Contracts [Member]
Potential Milestone Payments				15,500
Contractual Obligation				$ 66,000
Minimum [Member] | Clinical Trial Contracts [Member]
Termination Notice Period (Day)				30 days
Maximum [Member] | Clinical Trial Contracts [Member]
Termination Notice Period (Day)				45 days
Pfizer License Agreement [Member]
Potential Milestone Payments					12,500
Takeda [Member]
Milestone Payments Maximum Amount					287,300
Upfront License Fee								$ 7,000
Acquired In-process Research and Development					7,000
NERLYNX [Member]
Revenue from Contract with Customer, Including Assessed Tax					$ 250,000